{"paper_id":"433d963f-dbe2-46f5-ad92-d6c6b66c0ff2","body_text":"Introduction\nCesarean scar ectopic pregnancy (CSEP) is a pregnancy implanted in or in close contact with a niche in a previous cesarean delivery scar. Although uncommon, it can progress toward the bladder and serosa, or into the uterine cavity, and is associated with major hemorrhage, uterine rupture, hysterectomy, and placenta accreta spectrum (PAS) if the pregnancy continues. The increasing number of cesarean deliveries makes reliable recognition of this condition increasingly relevant[].\nHIGHLIGHTS\nCesarean scar ectopic pregnancy (CSEP) remains a rare but increasingly encountered entity due to rising global cesarean section rates, necessitating heightened clinical vigilance.\nCSEP presents significant diagnostic challenges, with clinical manifestations ranging from asymptomatic cases to presentations that mimic miscarriage, thereby emphasizing the critical role of early transvaginal ultrasound.\nMisdiagnosis and inappropriate initial management (e.g., the use of misoprostol for a presumed miscarriage) can delay definitive care and increase the risk of complications such as hemorrhage and uterine rupture.\nTimely surgical intervention with histopathological confirmation offers effective management and favorable outcomes, highlighting the importance of individualized, multidisciplinary care.\nDiagnosis is primarily sonographic. Transvaginal ultrasound provides the best assessment of the implantation site and residual myometrium, while transabdominal ultrasound may be the initial examination and can complement the evaluation of the uterus, bladder, and hemoperitoneum. Standardized reporting should document the relationship of the pregnancy to the scar niche, uterine cavity, cervical canal, and bladder; residual myometrial thickness; embryonic cardiac activity; and peri-trophoblastic vascularity[,].\nEvidence from a systematic review indicates substantially more severe morbidity when CSEP is diagnosed after 9 weeks rather than at or before 9 weeks[]. We present two surgically managed cases from Tanzania, including one initially treated with misoprostol for presumed missed abortion. The series highlights diagnostic pitfalls and practical management considerations where advanced imaging and interventional radiology may not be readily available. These case reports have been reported in line with the SCARE checklist[].\nPatient and observation\nCase 1\nA 38-year-old woman, Gravida 3, Para 2, Living 2, with a history of two previous cesarean deliveries, presented to the outpatient gynecology clinic in 2023 with a 17-week history of amenorrhea. Her chief complaint was lower abdominal pain, exacerbated by sexual intercourse. She denied vaginal bleeding, fever, gastrointestinal symptoms, urinary symptoms, or systemic complaints. Her obstetric history included two lower-segment cesarean sections: the first 6 years earlier for failure to progress, and the second 1-year earlier because of a previous cesarean scar. She had no known medical comorbidities apart from a documented allergy to sulfur-containing medications (she did not recall the exact medication). On examination, the patient was alert, oriented, afebrile, and hemodynamically stable. There were no signs of anemia or peripheral edema. Abdominal examination revealed a Pfannenstiel scar with localized suprapubic tenderness; bowel sounds were normal, and there was no rebound tenderness or guarding. Serum β-human chorionic gonadotropin (β-hCG) was 13 016 mIU/mL (laboratory reference: normal menstruating female < 5.3 mIU/mL; postmenopausal < 8.3 mIU/mL). Hemoglobin was 10.5 g/dL, white cell count was 4.80 × 109/L and platelet count was 413 × 109/L; her blood group was O positive. A transvaginal ultrasound (Fig. 1) demonstrated a gestational sac implanted within the anterior uterine wall at the site of the previous cesarean scar, with absent myometrial tissue between the sac and the bladder – consistent with a diagnosis of CSEP.\nThe patient underwent an emergency laparotomy. Intraoperatively, an ectopic pregnancy was confirmed at the site of the previous uterine scar and was successfully excised. A single intramuscular dose of methotrexate (50 mg) was administered postoperatively as adjuvant therapy.\nHistopathological examination demonstrated chorionic villi lined by trophoblastic cells, confirming products of conception (Fig. 2A, B). Serial serum β-hCG monitoring demonstrated a progressive decline from 13 016 mIU/mL on admission to 2304 mIU/mL 2 days later and 405 mIU/mL 6 days after admission. Approximately 2 months later, the level was 0.84 mIU/mL, confirming biochemical resolution.\nCase 2\nA 40-year-old gravida 7, para 6, with seven living children, presented after 18 weeks of amenorrhea with 4 days of progressively worsening lower abdominal pain and vaginal bleeding of approximately two pads per day. At 14 weeks of amenorrhea, she had been diagnosed at another healthcare facility with a presumed missed abortion and had received misoprostol. The pregnancy was not expelled. She reported no passage of tissue or foul-smelling discharge. She also reported dysuria without hematuria or urinary frequency. Her obstetric history included one cesarean delivery for malpresentation in a twin pregnancy, followed by five uncomplicated vaginal births.\nShe was alert, pale, afebrile, and in mild distress from pain, but was hemodynamically stable. Abdominal examination demonstrated suprapubic tenderness without peritonism. Hemoglobin was 11.7 g/dL, white-cell count 8.87 × 109/L, platelet count 282 × 109/L and C-reactive protein 231.05 mg/L (laboratory reference range 0.5–5 mg/L); there was a low β hCG level of 7.46 mIU/mL (laboratory reference range: normal menstruating female, < 5.3 mIU/mL; postmenopausal, <8.3 mIU/mL), and her blood group was A positive. Initial treatment included intravenous crystalloid, paracetamol, and ceftriaxone–sulbactam 1500 mg given intravenously.\nTransvaginal ultrasound (Fig. 3) revealed a non-viable fetus implanted at the site of the previous cesarean scar, with characteristic findings of CSEP at approximately 14 weeks gestation. An emergency laparotomy was performed, during which a non-viable fetus was identified within the cesarean scar (Supplemental Digital Content Figure S1, available at: https://links.lww.com/IJSCR/A235). The ectopic gestation was surgically removed, and hemostasis was achieved. Histopathology showed immature chorionic villi, membranes, and decidual tissue with areas of infarction, hemorrhage, neutrophilic infiltration, and calcification (Supplemental Digital Content Figure S2 (A–C), available at: https://links.lww.com/IJSCR/A235); the reported impression was placental tissue with acute chorioamnionitis. Her postoperative recovery was reported as uncomplicated, and she was discharged in stable condition with follow-up arranged.\nDiscussion\nCSEP, although the rarest variant of ectopic pregnancy, poses a substantial clinical challenge due to its often-subtle presentation and potentially life-threatening complications[]. CSEP results from implantation of the blastocyst within a microscopic defect or area of dehiscence at the site of a previous cesarean section scar. This defect may arise from poor healing, repeated cesarean deliveries, uterine instrumentation, or short interpregnancy intervals[].\nTwo distinct types of CSEP have been described based on the direction of trophoblastic invasion: Type I (endogenic) refers to pregnancies that grow toward the uterine cavity, while Type II (exogenic) involves implantation deep within the scar, growing outward toward the bladder or abdominal cavity. This classification has both diagnostic and prognostic value. Type I cases may progress to viable pregnancies, albeit with elevated risks, while Type II is associated with a higher likelihood of rupture and adverse maternal outcomes[].\nTransvaginal ultrasound with color Doppler is the imaging modality of choice for early and accurate detection. Typical sonographic findings include a gestational sac located anteriorly at the level of the uterine isthmus, embedded at the site of a previous cesarean scar, with an empty uterine cavity and cervical canal. The myometrial layer between the bladder and gestational sac may be thinned or completely absent, and increased vascularity at the implantation site is often observed[]. In later gestation, fetal structures such as the yolk sac, fetal pole, or even cardiac activity may become visible. In cases where ultrasound findings are equivocal or when deep invasion is suspected, magnetic resonance imaging can provide additional detail, particularly in assessing the PAS, although it is not routinely indicated[].\nThere is no single optimal treatment for all cases of CSEP. Management should consider hemodynamic status, gestational age, cardiac activity, residual myometrial thickness, direction of growth, vascularity, reproductive preferences, expertise, and available resources. Current Society for Maternal-Fetal Medicine guidance recommends against expectant management, systemic methotrexate alone, and sharp curettage alone; it supports operative resection or ultrasound-guided uterine aspiration and considers intragestational methotrexate with or without other modalities[]. Contemporary syntheses likewise show heterogeneous evidence and emphasize tailoring treatment rather than selecting a universal approach[].\nBoth patients in this series underwent laparotomy. Open excision can provide rapid exposure, direct hemorrhage control, removal of the gestation, and repair of the scar defect, and may be reasonable for advanced or deeply implanted pregnancies, or where laparoscopy, hysteroscopy, and interventional radiology are unavailable. Case 1 received adjuvant methotrexate to ensure complete trophoblastic regression, as evidenced by declining β-hCG levels[]. These cases illustrate the variable clinical spectrum of CSEP and reinforce the importance of early recognition, appropriate imaging, and timely intervention. Multidisciplinary management involving obstetricians, radiologists, anesthesiologists, and, where necessary, interventional radiologists is essential to optimize outcomes and preserve reproductive potential.\nConclusion\nCSEP is a rare but serious obstetric complication that requires a high index of suspicion, especially in women with a history of cesarean delivery. Early and accurate diagnosis, primarily through transvaginal ultrasound, is essential to prevent severe maternal morbidity and preserve fertility. Surgical management remains a safe and effective treatment option, particularly in advanced gestations or in symptomatic patients. Multidisciplinary care and timely intervention are key to optimizing patient outcomes and minimizing complications.\nEthical approval\nCase report is exempted from ethical approval in my institution (The Aga Khan University, Medical college East Africa, Dar es Salaam, Tanzania).\nConsent\nWritten informed consent was obtained from the patient for publication of this case series. A copy of the written consents are available for review by the Editor-in and Chief of this journal on request. accompanying images.\nSources of funding\nThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.\nAuthor contributions\nL.M., D.M.: Manuscript drafting, data collection. M.L.M., S.J.: Manuscript revision and patient management. C.N.: Histology interpretation. Z.F.: Radiology interpretation.\nConflicts of interest disclosure\nThe authors declare no competing interest.\nResearch registration unique identifying number (UIN)\nNot applicable.\nGuarantor\nNot applicable.\nProvenance and peer review\nNot applicable.\nPatient perspective\nBoth patients were glad of early detection of the condition and timely surgical interventions provided.\nData availability statement\nNot applicable.\nAcknowledgements\nWe dedicate this work to the late Dr. Wilbroad Kyejo, a compassionate Family Physician whose passion for research, mentorship, and service profoundly shaped our professional journeys. Dr. Kyejo was actively involved in the development of numerous manuscripts, including this case series, and his sudden passing left a void felt deeply by all who worked with him. His commitment to scientific inquiry and improving patient care continues to inspire us.\nWe honour his memory with gratitude and respect, and we hope that this work reflects the spirit of dedication he embodied throughout his career.\nReferences\n[1]\nBetran A, Ye J, Moller A-B, et al. Trends and projections of caesarean section rates: global and regional estimates. BMJ Glob Health 2021;6:e005671.[2]\nJordans IPM, Verberkt C, De Leeuw RA, et al. Definition and sonographic reporting system for Cesarean scar pregnancy in early gestation: modified Delphi method. Ultrasound Obstetrics Gynecol 2022;59:437–49.[3]\nMiller R, Gyamfi-Bannerman C. Society for maternal-fetal medicine consult series #63: cesarean scar ectopic pregnancy. Am J Obstet Gynecol 2022;227:B9–b20.[4]\nSalomon LJ, Alfirevic Z, Berghella V, et al. ISUOG practice guidelines (updated): performance of the routine mid-trimester fetal ultrasound scan. Ultrasound Obstetrics Gynecol 2022;59:840–56.[5]\nTimor-Tritsch IE, Monteagudo A. Unforeseen consequences of the increasing rate of cesarean deliveries: early placenta accreta and cesarean scar pregnancy. A review. Am J Obstet Gynecol 2012;207:14–29.[6]\nKerwan A, Al-Jabir A, Mathew G, et al. Revised Surgical CAse REport (SCARE) guideline: an update for the age of artificial intelligence. Prem J Sci 2025;10:100079.[7]\nKang SY, Park BJ, Kim YW, et al. Surgical management of cesarean scar ectopic pregnancy: hysterotomy by transvaginal approach. Fertil Steril 2011;96:e25–8.[8]\nTantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 2008;29:639–45.[9]\nBirch Petersen K, Hoffmann E, Rifbjerg Larsen C, et al. Cesarean scar pregnancy: a systematic review of treatment studies. Fertil Steril 2016;105:958–67.[10]\nBouyer J, Coste J, Fernandez H, et al. Sites of ectopic pregnancy: a 10 year population-based study of 1800 cases. Hum Reprod 2002;17:3224–30.[11]\nSeow KM, Huang LW, Lin YH, et al. Cesarean scar pregnancy: issues in management. Ultrasound Obstet Gynecol 2004;23:247–53.[12]\nKaelin Agten A, Cali G, Monteagudo A, et al. The clinical outcome of cesarean scar pregnancies implanted “on the scar” versus “in the niche.” Am J Obstet Gynecol 2017;216:510.e1–.e6.[13]\nAlameddine S, Lucidi A, Jurkovic D, et al. Treatments for cesarean scar pregnancy: a systematic review and meta-analysis. J Maternal-Fetal Neonatal Med 2024;37:2327569.[14]\nFu P, Sun H, Zhang L, et al. Efficacy and safety of treatment modalities for cesarean scar pregnancy: a systematic review and network meta-analysis. Am J Obstet Gynecol MFM 2024;6:101328.[15]\nKłobuszewski B, Szmygin M, Nieoczym K, et al. Advances in treating cesarean scar pregnancy: a comprehensive review of techniques, clinical outcomes, and fertility preservation. Med Sci Monit 2024;30:e943550.","source_license":"CC0","license_restricted":false}